Author

R. J. Dickmander

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 3 Immunology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Organism:human· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

J. L. Smith· 4 shared N. J. Moorman· 4 shared T. M. Willson· 4 shared A. D. Axtman· 3 shared E. A. Madden· 2 shared E. Chang· 2 shared J. W. Brown· 2 shared M. T. Heise· 2 shared

Activity by Year

2022-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCell Biology

J. L. Smith

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Synthesis of 5-Benzylamino and 5-Alkylamino-substituted Pyrimidoquinoline Derivatives as CSNK2A Inhibitors with Antiviral Activity

K. H. Asressu, J. L. Smith, R. J. Dickmander, N. J. Moorman, J. Wellnitz, K. I. Popov, A. D. Axtman, T. M. Willson

The paper synthesizes pyrimidoquinoline derivatives as CSNK2A inhibitors with antiviral activity, finding that certain substituents improve potency while maintaining solubility.

bioRxiv · Jan 30, 2024Cell Biology

Identification of 4-(6-((2-methoxyphenyl)amino)pyrazin-2-yl)benzoic acids as CSNK2A inhibitors with antiviral activity and improved selectivity over PIM3

K. Galal, A. Kramer, B. G. Strickland, J. L. Smith, R. J. Dickmander, N. J. Moorman, T. M. Willson

bioRxiv · Dec 4, 2023Cell Biology

Lethal COVID-19 Associates With RAAS-Induced Inflammation For Multiple Organ Damage Including Mediastinal Lymph Nodes

J. W. Guarnieri, M. Topper, K. Beigel, J. A. Haltoom, A. Chadburn, J. Frere, J. An, H. Cope, A. Borczuk, S. Sinha, C. Lim, J. Kim, J. Park, C. Meydan, J. Foox, , K Clark

This study identifies non-canonical genes linked to RAAS overactivation in lethal COVID-19, causing multi-organ damage and mediastinal lymph node dysfunction.

bioRxiv · Oct 8, 2023 · PreprintImmunology

Optimization of 3-Cyano-7-cyclopropylamino-pyrazolopyrimidines Toward the Development of an In Vivo Chemical Probe for CSNK2

X. Yang, H. W. Ong, R. J. Dickmander, J. L. Smith, J. W. Brown, W. Tao, E. Chang, N. J. Moorman, A. D. Axtman, T. M. Willson

The paper develops analogs of SGC-CK2-1 to improve pharmacokinetic properties in mice by inhibiting GST and P450 enzymes through co-dosing protocols.

bioRxiv · May 15, 2023Pharmacology & Toxicology

Host kinase CSNK2 is a target for inhibition of pathogenic β-coronaviruses including SARS-CoV-2

X. Yang, R. J. Dickmander, A. Bayati, S. A. Taft-Benz, J. L. Smith, C. I. Wells, E. A. Madden, J. W. Brown, E. M. Lenarcic, B. L. Yount, E. Chang, A. D. Axtman, R. S. Baric, M. T. Heise, P. S. McPherson, , T. M. Willson

The paper shows that inhibiting the kinase CSNK2 blocks replication of several beta-coronaviruses, including SARS-CoV-2, by preventing viral entry.

bioRxiv · Jan 3, 2022 · PreprintCell Biology